4 Mar
2020

What the current wave of biosimilar litigation signals for the future

There has been a swell of US patent disputes between biologics innovators and makers of biosimilars in the past six years. With litigation governed by a highly distinctive legal and regulatory framework, IP professionals can learn plenty from recent cases

Adam Houldsworth

Life sciences reporter

IAM

[email protected]